Press release
Ovarian Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therap
"Ovarian Cancer Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.
The Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Ovarian Cancer Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Ovarian Cancer treatment therapies with a considerable amount of success over the years.
*
Ovarian Cancer companies working in the treatment market are Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others, are developing therapies for the Ovarian Cancer treatment
*
Emerging Ovarian Cancer therapies in the different phases of clinical trials are- Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others are expected to have a significant impact on the Ovarian Cancer market in the coming years.
*
In December 2025, Daiichi Sankyo has reported the first patient dosing in the randomization phase of the DESTINY-Ovarian01 Phase III trial, which is evaluating Enhertu (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab alone as a first-line maintenance therapy for ovarian cancer. The study targets patients with HER2-expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer who have completed initial treatment with platinum-based chemotherapy plus bevacizumab. This randomized, global, multi-center, open-label Phase III trial is designed to assess the safety and efficacy of the Enhertu (5.4 mg/kg) combination in the specified patient population.
*
In November 2025, Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage biopharmaceutical company advancing stenoparib (2X-121)-a unique dual PARP and WNT pathway inhibitor announced its financial results and operational progress for the third quarter ending September 30, 2025. The company noted that Q3 2025 marked significant achievements, including receiving FDA Fast Track designation for stenoparib in advanced ovarian cancer, underscoring the promise of its lead program. Allarity also shared encouraging new clinical data demonstrating a median overall survival of more than 25 months in its Phase 2 trial, a notable outcome for this challenging patient population.
*
In April 2025, Corcept Therapeutics' key Phase III ROSELLA trial evaluating oral relacorilant combined with nab-paclitaxel has successfully achieved its primary goal by showing an improvement in progression-free survival (PFS) in patients with platinum-resistant ovarian cancer. The study included 381 participants from Argentina, Brazil, Canada, Europe, Australia, and South Korea, and demonstrated a 30% reduction in the risk of disease progression for those receiving the combination therapy compared to nab-paclitaxel alone.
*
In March 2025, Imunon announced that the US Food and Drug Administration (FDA) has aligned with the Phase III OVATION 3 trial protocol for IMNN-001 in ovarian cancer. IMNN-001, the company's lead drug candidate, is being developed to treat women newly diagnosed with advanced ovarian cancer. Imunon is now opening clinical trial sites and working with investigators to begin enrolling participants.
*
In March 2025, AbbVie, a US-based pharmaceutical company, has released the final analysis of its Phase III MIRASOL trial evaluating the antibody-drug conjugate (ADC) Elahere compared to chemotherapy for platinum-resistant ovarian cancer (PROC). This randomized trial examined the safety and effectiveness of the treatment in women with folate receptor alpha (FR) positive PROC.
*
In August 2024, South Korean biopharmaceutical company CanariaBio has completed patient enrollment for a Phase II clinical trial investigating oregovomab in combination with chemotherapy for advanced epithelial ovarian cancer. Known as FLORA-6, this double-blind, placebo-controlled, multicenter trial is designed to evaluate oregovomab alongside chemotherapy agents paclitaxel and carboplatin as a neo-adjuvant treatment for newly diagnosed patients.
Ovarian Cancer Overview
Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and hormones. It typically develops when abnormal cells in the ovaries grow uncontrollably and form tumors. Ovarian cancer is often referred to as a "silent" disease because its symptoms can be vague or go unnoticed until the cancer is advanced. Common symptoms may include bloating, pelvic pain, frequent urination, and difficulty eating. Early detection can be challenging, but with treatment options such as surgery, chemotherapy, and targeted therapies, the prognosis can improve, especially if caught in its early stages.
Get a Free Sample PDF Report to know more about Ovarian Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight [https://www.delveinsight.com/report-store/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:
*
Olaparib: Mario Negri Institute
*
Niraparib: Tesaro, Inc.
*
MORAb-202: Bristol-Myers Squibb
*
Paclitaxel: Merck Sharp & Dohme
*
Vigil: Gradalis, Inc.
*
olaparib: AGO Research GmbH
*
Pembrolizumab: Haider Mahdi
*
Olaparib: AstraZeneca
*
JAB-8263: Jacobio Pharmaceuticals
*
Nirogacestat: SpringWorks Therapeutics
*
TAK-853: Takeda
*
SHR-A1921: Suzhou Suncadia Biopharmaceutical
*
Tuvusertib (M1774): EMD Serono Research
*
Ipatasertib: Hoffmann-La Roche
*
Paclitaxel: Anhui Provincial Cancer Hospital
*
BD0801: Jiangsu Simcere Pharmaceutical
Ovarian Cancer Route of Administration
Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical.
Ovarian Cancer Molecule Type
Ovarian Cancer Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Ovarian Cancer Pipeline Therapeutics Assessment
*
Ovarian Cancer Assessment by Product Type
*
Ovarian Cancer By Stage and Product Type
*
Ovarian Cancer Assessment by Route of Administration
*
Ovarian Cancer By Stage and Route of Administration
*
Ovarian Cancer Assessment by Molecule Type
*
Ovarian Cancer by Stage and Molecule Type
DelveInsight's Ovarian Cancer Report covers around 200+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Ovarian Cancer product details are provided in the report. Download the Ovarian Cancer pipeline report to learn more about the emerging Ovarian Cancer therapies [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Ovarian Cancer Therapeutics Market include:
Key companies developing therapies for Ovarian Cancer are - Pfizer, Daiichi Sankyo, Inc., Astellas Pharma Inc, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, ImmunoGen, OncoQuest, Lee's Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Bayer, Xennials Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Puma Biotechnology, Inc., MaxCyte, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., and others.
Ovarian Cancer Pipeline Analysis:
The Ovarian Cancer pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Ovarian Cancer with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.
*
Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Ovarian Cancer drugs and therapies [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Ovarian Cancer Pipeline Market Drivers
*
Increasing prevalence of Ovarian Cancer, increasing research and development activities, launch of novel drugs are some of the important factors that are fueling the Ovarian Cancer Market.
Ovarian Cancer Pipeline Market Barriers
*
However, huge expenditure of the treatment methods, adverse effects associated with the drugs and other factors are creating obstacles in the Ovarian Cancer Market growth.
Scope of Ovarian Cancer Pipeline Drug Insight
*
Coverage: Global
*
Key Ovarian Cancer Companies: Mario Negri Institute, Tesaro, Inc., Bristol-Myers Squibb, Merck Sharp & Dohme, Gradalis, Inc., AGO Research GmbH, Haider Mahdi, AstraZeneca, Jacobio Pharmaceuticals, SpringWorks Therapeutics, Takeda, Suzhou Suncadia Biopharmaceutical, EMD Serono Research, Hoffmann-La Roche, Anhui Provincial Cancer Hospital, Jiangsu Simcere Pharmaceutical, and others
*
Key Ovarian Cancer Therapies: Olaparib, Niraparib, MORAb-202, Paclitaxel, Vigil, olaparib, Pembrolizumab, Olaparib, JAB-8263, Nirogacestat, TAK-853, SHR-A1921, Tuvusertib (M1774), Ipatasertib, Paclitaxel, BD0801, and others
*
Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
*
Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers
Request for Sample PDF Report for Ovarian Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Ovarian Cancer Report Introduction
2. Ovarian Cancer Executive Summary
3. Ovarian Cancer Overview
4. Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment
5. Ovarian Cancer Pipeline Therapeutics
6. Ovarian Cancer Late Stage Products (Phase II/III)
7. Ovarian Cancer Mid Stage Products (Phase II)
8. Ovarian Cancer Early Stage Products (Phase I)
9. Ovarian Cancer Preclinical Stage Products
10. Ovarian Cancer Therapeutics Assessment
11. Ovarian Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ovarian Cancer Key Companies
14. Ovarian Cancer Key Products
15. Ovarian Cancer Unmet Needs
16 . Ovarian Cancer Market Drivers and Barriers
17. Ovarian Cancer Future Perspectives and Conclusion
18. Ovarian Cancer Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=ovarian-cancer-pipeline-2025-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-pfizer-daiichi-sankyo-astellas-pharma-jiangsu-hengrui-boehringer-ingelheim-impact-therap]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Ovarian Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therap here
News-ID: 4311972 • Views: …
More Releases from ABNewswire
Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase …
Actinium Pharmaceuticals (NYSE American: ATNM) is advancing its Trop-2-targeted ATNM-400 construct into Phase 1/2 trials across the United States and Australia, marking an important step as the company broadens its presence in solid-tumor radiopharmaceuticals. With targeted alpha radiotherapy gaining momentum worldwide, the program reinforces Actinium's position as one of the more established players developing actinium-225-based therapeutics for treatment-resistant and late-stage cancers.
Why Trop-2 Remains One of Oncology's Most Valuable Targets
Trop-2 has…
Mucopolysaccharidosis Type I Market Dynamics Indicate Upward Trajectory Through …
The Key Mucopolysaccharidosis Type I Companies in the market include - BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others.
DelveInsight's "Mucopolysaccharidosis Type I Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Mucopolysaccharidosis Type I, historical and forecasted epidemiology as well as the Mucopolysaccharidosis Type I market trends in the…
United Chimney Services Shares Essential Fireplace Safety Tips for Clifton Homeo …
United Chimney Services, serving Clifton and surrounding New Jersey communities, is sharing expert fireplace safety tips as winter increases fire and smoke-related risks. Owner Daniel Ward encourages homeowners to schedule inspections, remove creosote buildup, check ventilation, and practice safe fireplace use to reduce preventable hazards.
United Chimney Services is urging Clifton homeowners to prioritize fireplace safety this winter as colder weather increases the risk of chimney fires, smoke damage, and carbon…
KinClub Launches New Interactive Kids Magazine, Debuting With a Holiday Issue Th …
December 11, 2025 - New York, NY - Kinovate Ventures, Inc. today announced the launch of KinClub Magazine, a dynamic new digital publication designed to engage children through a vast library of interactive pages and adaptive learning experiences. The magazine officially debuts with its first major release, the KinClub Holiday Issue [https://magazine.kin-club.com/the-holiday-season-2025], now available for free.
Key features of the KinClub Magazine experience include:
*
A Blend of Classic & Creative: The content…
More Releases for Ovarian
Ovarian Cancer Diagnostics Market Size: 2033 Statistics
The Ovarian Cancer Diagnostics market is expected to grow from an estimated USD 4814.5 million in 2024 to USD 7795.1 million in 2033, at a CAGR of 5.50%.
The ovarian cancer diagnostics market plays a critical role in the early detection and management of ovarian cancer, one of the most common and lethal gynecological cancers worldwide. Ovarian cancer is often diagnosed at an advanced stage due to the lack of noticeable…
Ovarian Cancer Market Size, Future Trends
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Ovarian Cancer Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
How deadly is Ovarian Cancer?
Ovarian Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body.
The global Ovarian Cancer Treatment Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025,…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
Ovarian Cancer - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Ovarian Cancer - Heat Map and Analysis to its growing collection of premium market research reports.
Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in women, and the most common gynecological cancer, with an estimated 225,000 new cases diagnosed globally in 2008. Rates are particularly high in developed countries, and especially in Northern Europe. However, substantial improvements in…
